Kymera Therapeutics (KYMR)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$2.59 (+5.88%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Kymera Therapeutics (KYMR)
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Key Insights

Critical company metrics and information

  • Share Price

    $46.67

  • Market Cap

    $3.02 Billion

  • Total Outstanding Shares

    64.77 Million Shares

  • Total Employees

    184

  • Dividend

    No dividend

  • IPO Date

    August 21, 2020

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.kymeratx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$29.66 Million
Net Cash Flow From Investing Activities$-453.69 Million
Net Cash Flow From Operating Activities$-124.67 Million
Net Cash Flow From Financing Activities, Continuing$608.02 Million
Net Cash Flow From Investing Activities, Continuing$-453.69 Million
Net Cash Flow$29.66 Million
Net Cash Flow From Operating Activities, Continuing$-124.67 Million
Net Cash Flow From Financing Activities$608.02 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0.00
Operating Expenses$287.75 Million
Basic Earnings Per Share$2.34
Net Income/Loss Attributable To Parent$-167.47 Million
Other Operating Expenses$66.35 Million
Diluted Average Shares$220.01 Million
Benefits Costs and Expenses$188.81 Million
Operating Income/Loss$-200.19 Million
Net Income/Loss Available To Common Stockholders, Basic$-167.47 Million
Basic Average Shares$220.01 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Revenues$87.56 Million
Income/Loss From Continuing Operations After Tax$-167.47 Million
Costs And Expenses$264.67 Million
Research and Development$221.40 Million
Income/Loss From Continuing Operations Before Tax$-101.25 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss$-167.47 Million
Diluted Earnings Per Share$2.34

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities$141.91 Million
Other Current Liabilities$60.04 Million
Accounts Payable$6.49 Million
Equity$892.93 Million
Noncurrent Assets$466.13 Million
Current Assets$568.72 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$1.03 Billion
Fixed Assets$51.24 Million
Liabilities And Equity$1.03 Billion
Current Liabilities$66.53 Million
Equity Attributable To Parent$892.93 Million
Other Non-current Assets$414.88 Million
Noncurrent Liabilities$75.38 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.